172854-76-1
Chemical Structure
Cacospongionolide B
- CAS No.: 172854-76-1
- Formula:C25H36O4
- Molecular Weight:400.55
InChIKey: CVAZWHZRZNYCOV-DRCQBYJMSA-N
SMILES: O=C(O[C@H]1O)C=C1[C@H](OC2)CC=C2CC[C@@]3([C@]4([H])[C@@](CC[C@@H]3C)(C(CCC4)=C)C)C
Biological Activity: Cacospongionolide B is an orally active sesterterpene compound that can be isolated from Fasciospongia cavernosa. Cacospongionolide B is a secreted phospholipase A2 (sPLA2) inhibitor with an IC50 of 4.3 μM. Cacospongionolide B exhibits antibacterial activity. Cacospongionolide B downregulates the expression of iNOS, COX-2 and TNF-α by inhibiting NF-κB nuclear translocation and its DNA binding, and simultaneously selectively and irreversibly inhibits sPLA2 enzymatic activity. Cacospongionolide B can be used in studies related to bacterial infection and adjuvant arthritis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cacospongionolide B | Cacospongionolide B is an orally active sesterterpene compound that can be isolated from Fasciospongia cavernosa. Cacospongionolide B is a secreted phospholipase A2 (sPLA2) inhibitor with an IC50 of 4.3 μM. Cacospongionolide B exhibits antibacterial activity. Cacospongionolide B downregulates the expression of iNOS, COX-2 and TNF-α by inhibiting NF-κB nuclear translocation and its DNA binding, and simultaneously selectively and irreversibly inhibits sPLA2 enzymatic activity. Cacospongionolide B can be used in studies related to bacterial infection and adjuvant arthritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. De Rosa S, et al. Cacospongionolide B, a new sesterterpene from the sponge Fasciospongia cavernosa. Journal of natural products. 1995 Nov;58(11):1776-80.
- [2]. Posadas I, et al. Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-alpha by inhibiting nuclear factor-kappa B activation. British journal of pharmacology. 2003 Apr;138(8):1571-9.
- [3]. García Pastor P, et al. Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2. British journal of pharmacology. 1999 Jan;126(1):301-11.
